Oncopeptides AB Gains Spotlight with Real-World Data Acceptance at IMS Annual Meeting

In a significant development for the biotechnology sector, Oncopeptides AB, a pharmaceutical company based in Stockholm, Sweden, has announced the acceptance of two real-world evidence (RWE) posters for presentation at the International Myeloma Society’s (IMS) Annual Meeting in Toronto, scheduled for September 17-20, 2025. This announcement, made on July 23, 2025, highlights the company’s ongoing efforts to advance cancer treatment through innovative therapies.

The RWE posters, which have been accepted for presentation, are based on data from Spain and Italy. These datasets provide insights into the effectiveness of Oncopeptides’ drug, Pepaxti, in real-world clinical settings. The data specifically pertains to pre-treated patients with multiple myeloma, offering valuable information on the drug’s performance outside of controlled clinical trials.

Oncopeptides AB operates within the health care sector, focusing on biotechnology and listed on the Swedish Stock Exchange. The company is renowned for its proprietary technology that enhances the efficacy of cytotoxic compounds through the development of pro-drugs. This innovative approach aims to improve treatment outcomes for patients with difficult-to-treat cancers.

As of July 21, 2025, Oncopeptides AB’s stock closed at 4.035 SEK, with a 52-week high of 4.855 SEK on July 10, 2025, and a low of 1.1 SEK on March 17, 2025. The company’s market capitalization stands at approximately 719,353,587 SEK, reflecting its position within the biotechnology industry.

The acceptance of these RWE posters at the IMS Annual Meeting is a testament to Oncopeptides’ commitment to advancing cancer treatment and its potential impact on the healthcare sector. The presentation of this data at a prestigious international conference underscores the company’s role in the global effort to combat cancer through innovative therapies.

As the biotechnology sector continues to evolve, Oncopeptides AB’s focus on real-world data and its implications for treatment efficacy positions the company as a key player in the development of next-generation cancer therapies. The upcoming IMS Annual Meeting will provide a platform for Oncopeptides to share its findings with the international medical community, potentially influencing future treatment protocols and research directions in the fight against cancer.